Chasseloup F, Bernard V, Chanson P (2024) Prolactin: structure, receptors, and functions. Rev Endocr Metab Disord 25(6):953–966. https://doi.org/10.1007/s11154-024-09915-8

Article  CAS  PubMed  Google Scholar 

Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722–740. https://doi.org/10.1038/s41574-023-00886-5

Article  PubMed  Google Scholar 

Moult PJ, Rees LH, Besser GM (1982) Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea an the response to Bromocriptine therapy. Clin Endocrinol (Oxf) 16(2):153–162. https://doi.org/10.1111/j.1365-2265.1982.tb03159.x

Article  CAS  PubMed  Google Scholar 

Zirkin BR, Papadopoulos V (2018) Leydig cells: formation, function, and regulation. Biol Reprod 99(1):101–111. https://doi.org/10.1093/biolre/ioy059

Article  PubMed  PubMed Central  Google Scholar 

Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F et al (2022) Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian society of andrology and sexual medicine (SIAMS) and the Italian society of endocrinology (SIE). J Endocrinol Invest 45(12):2385–2403. https://doi.org/10.1007/s40618-022-01859-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A et al (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64(3):307–313. https://doi.org/10.1111/j.1365-2265.2006.02461.x

Article  CAS  PubMed  Google Scholar 

Calle-Rodrigue C RD, Giannini, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT et al (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11):1046–1052. https://doi.org/10.4065/73.11.1046

Al-Sharefi A, Quinton R (2020) Current National and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul) 35(3):526–540. https://doi.org/10.3803/EnM.2020.760

Article  PubMed  Google Scholar 

Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G et al (2019) Aggressive Malignant Prolactinomas Neuroendocrinol 109(1):57–69. https://doi.org/10.1159/000497205

Article  CAS  Google Scholar 

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. Oxford Academic, pp 273–288

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7–22. https://doi.org/10.1007/s11102-023-01360-1

Article  CAS  PubMed  Google Scholar 

Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888–3921. https://doi.org/10.1210/jc.2016-2118

Article  CAS  PubMed  Google Scholar 

Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing’s syndrome. Lancet 402(10418):2237–2252. https://doi.org/10.1016/S0140-6736(23)01961-X

Article  PubMed  Google Scholar 

Samperi I, Lithgow K, Karavitaki N, Hyperprolactinaemia (2019) J Clin Med 8(12). https://doi.org/10.3390/jcm8122203

Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA et al (2019) Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 5(1):38. https://doi.org/10.1038/s41572-019-0087-y

Article  PubMed  PubMed Central  Google Scholar 

Tsametis CP, Isidori AM (2018) Testosterone replacement therapy: for whom, when and how? Metabolism. 86:69–78. https://doi.org/10.1016/j.metabol.2018.03.007

Zitzmann M (2020) Testosterone, mood, behaviour and quality of life. Andrology 8(6):1598–1605. https://doi.org/10.1111/andr.12867

Article  CAS  PubMed  Google Scholar 

Yeo S, Holl K, Penaherrera N, Wissinger U, Anstee K, Wyn R (2021) Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: A narrative review. Clinicoecon Outcomes Res 13:31–38. https://doi.org/10.2147/CEOR.S285434

Article  PubMed  PubMed Central  Google Scholar 

Constantinescu SM, Maiter D, Alexopoulou O (2024) Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists. Pituitary 27(5):625–634. https://doi.org/10.1007/s11102-024-01445-5

Article  CAS  PubMed  Google Scholar 

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x

Article  PubMed  Google Scholar 

Voica M, Tetlay M, Thompson DV, Hasan F (2021) Recovery of male hypogonadism following successful treatment of prolactinoma: the experience of an integrated health network. J Endocr Soc 5(Supplement1):A632–A3. https://doi.org/10.1210/jendso/bvab048.1289

Article  PubMed Central  Google Scholar 

Guitelman MA, Cardenas G, Rogozinski A, Ballarino C, Battistone MF, Danilowicz K et al (2024) 12342 retrospective multicenter study of prolactinomas in men. J Endocr Soc 8(Supplement1). https://doi.org/10.1210/jendso/bvae163.1323

Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK et al (2020) Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on Cabergoline. J Clin Endocrinol Metab 105(12). https://doi.org/10.1210/clinem/dgaa650

Al Dahmani KM, Almalki MH, Ekhzaimy A, Aziz F, Bashier A, Mahzari MM et al (2022) Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658–666. https://doi.org/10.1007/s11102-022-01242-y

Article  CAS  PubMed  Google Scholar 

Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882–890. https://doi.org/10.1007/s11102-022-01259-3

Article  CAS  PubMed  Google Scholar 

De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L et al (2004) Six months of treatment with Cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89(2):621–625. https://doi.org/10.1210/jc.2003-030852

Article  CAS  PubMed  Google Scholar 

Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH et al (2002) Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5(4):243–246. https://doi.org/10.1023/a:1025377816769

Article  PubMed  Google Scholar 

Rudman Y, Simon N, Shimon R, Drozdinsky G, Markus E, Duskin-Bitan H et al (2025) Response to Cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study. Endocrine. https://doi.org/10.1007/s12020-025-04215-w

Article  PubMed  Google Scholar 

Fernandez CJ, Chacko EC, Pappachan JM (2019) Male Obesity-related secondary Hypogonadism - Pathophysiology, clinical implications and management. Eur Endocrinol 15(2):83–90. https://doi.org/10.17925/EE.2019.15.2.83

Article  PubMed  PubMed Central  Google Scholar 

Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M et al (2013) Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 168(6):829–843. https://doi.org/10.1530/EJE-12-0955

Article  CAS  PubMed  Google Scholar 

Barbonetti A, D’Andrea S, Francavilla S (2020) Testosterone replacement therapy. Andrology 8(6):1551–1566. https://doi.org/10.1111/andr.12774

Article  CAS  PubMed  Google Scholar 

Munari EV, Amer M, Amodeo A, Bollino R, Federici S, Goggi G et al (2023) The complications of male hypogonadism: is it just a matter of low testosterone? Front Endocrinol (Lausanne) 14:1201313. https://doi.org/10.3389/fendo.2023.1201313

Article  PubMed  Google Scholar 

Vakhshoori M, Heidarpour M, Bondariyan N, Sadeghpour N, Mousavi Z (2021) Adrenal insufficiency in coronavirus disease 2019 (COVID-19)-Infected patients without preexisting adrenal diseases: A systematic literature review. Int J Endocrinol 2021:2271514. https://doi.org/10.1155/2021/2271514

Article  CAS